{"id":6080,"date":"2019-12-07T09:31:10","date_gmt":"2019-12-07T08:31:10","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/gna-biosolutions-gibt-fuehrungswechsel-nach-abschluss-der-serie-c-bekannt\/"},"modified":"2020-07-03T09:29:54","modified_gmt":"2020-07-03T07:29:54","slug":"gna-biosolutions-gibt-fuehrungswechsel-nach-abschluss-der-serie-c-bekannt","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/gna-biosolutions-gibt-fuehrungswechsel-nach-abschluss-der-serie-c-bekannt\/","title":{"rendered":"GNA Biosolutions announces leadership changes following Series C closing"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

GNA Biosolutions announces leadership changes following Series C closing<\/span><\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]GNA closed the financing round with over 13.5 million US dollars[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]December 2019[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”6078″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 GNA Biosolutions[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Dr. Federico Buersgens<\/strong>, CEO, co-founder, Dr. Anastasia Liapis<\/strong>, Vice President Strategic Marketing & Partnerships, Dr. Lars Ullerich<\/strong>, CBO, co-founder, Dr. Joachim Stehr<\/strong>, CSO, co-founder, GNA Biosolutions (v.l.n.r.)[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]GNA Biosolutions, a developer of ultrafast molecular diagnostics platforms, announced\u00a0 leadership changes in conjunction with its plans to develop a Point of Care human diagnostics system, for which the company secured funding amounting to 13.5 million US dollars in 2019.<\/p>\n

“As we continue our efforts to bring our POC platform to the market, we are focused on ensuring that we have the right team and organizational structure in place. GNA\u2019s realignment of key leadership roles is intended to streamline our organizational structure for the next phase in our trajectory,” said co-founder and newly appointed Chief Executive Officer (CEO), Federico Buersgens.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote”][vc_column_inner][vc_column_text]<\/p>\n

\u00a9 GNA Biosolutions<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Further changes to GNA\u2019s leadership team comprise co-founder Dr. Lars Ullerich assuming responsibilities of Chief Business Officer (CBO) and co-founder Dr. Joachim Stehr assuming the duties of Chief Scientific Officer (CSO). Dr. Anastasia Liapis, who supported fundraising of GNA\u2019s 13.5 million US dollar Series C financing round, has been \u00adpromoted to VP to oversee Strategic Marketing & \u00adPartnerships.<\/p>\n

“We remain focused on our core technology development expertise, while further developing GNA\u2019s product pipeline. We are committed to delivering products for healthcare providers and the patients they serve.\u201d said Mr. Buersgens.
\nThe company\u2019s POC platform will \u00addiagnose \u00adinfectious diseases near the patient in just a few minutes, instead of traditional methods which can take hours.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n